XLON
FDBK
Market cap3mUSD
Oct 09, Last price
6.35GBP
1D
0.00%
1Q
-5.93%
Jan 2017
-98.49%
Name
Feedback PLC
Chart & performance
P/E
—
P/S
3.14
EPS
—
Div yield, %
—
Shrs. gr., 5y
51.05%
Rev. gr., 5y
15.98%
Revenues
886k
-25.05%
Net income
-7m
L+121.85%
CFO
-3m
L+27.06%
Dividend
Jul 10, 19950.4959 GBP/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Feedback plc is a medical technology company, headquartered in London, UK, and established in 1958, that supplies specialized software and systems to individuals and organizations working within the medical imaging sector. Their product portfolio includes TexRAD, a patented software tool designed to extract and quantify textural features within radiological images. This assists research into all types of tumors and helps uncover biomarkers in medical imagery. They also offer TexRAD Lung, a specific software tool used for the clinical analysis of lung cancer within the European Union. Additionally, the company provides the Cadran image platform, a robust picture archiving and communication system (PACS) for hospitals and research institutes, capable of handling images from various imaging modalities like CT and PET scanners. Another key offering is Bleepa, a secure platform for clinical communications that facilitates the safe sharing of high-quality medical images.
Key people
Alastair James Riddell
Non-Executive Chairman of the Board · since 2019
Thomas Oakley
Chief Executive Officer · since 2019
Rory Shaw
Non-Executive Deputy Chairman of the Board · since 2019
Lindsay Melvin
Chief Financial Officer · since 2018
Mark Peter Bird
Director - Sales, Executive Director · since 2011
Balaji Ganeshan
Director · since 2015
Michael Peter Hayball
Director · since 2015
Alexander Henry Menys
Director · since 2015
Non-Executive Director · since 2012
Timothy Norris Irish
Non-Executive Director · since 2017
Headquarters & legal address
201 TEMPLE CHAMBERS
3-7 TEMPLE AVENUE
TEMPLE
LONDON, LND EC4Y 0DT
GB
3-7 TEMPLE AVENUE
TEMPLE
LONDON, LND EC4Y 0DT
GB
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑05 | 2024‑05 | 2023‑05 | 2022‑05 | 2021‑05 | 2020‑05 | 2019‑05 | 2018‑05 | 2017‑05 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||